Victory Capital Management
AVXL icon

Victory Capital Management’s Anavex Life Sciences AVXL Stock Holding History

Victory Capital Management’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.9K Buy
10,379
+104
+1% +$308 ﹤0.01% 2434
2026
Q1 		$31.5K Buy
+10,275
New +$44.5K ﹤0.01% 2351
2025
Q1 		– Sell
-10,156
Closed -$109K – 2478
2024
Q4 		$109K Sell
10,156
-269
-3% -$2.07K ﹤0.01% 2330
2024
Q3 		$59.2K Sell
10,425
-172
-2% -$992 ﹤0.01% 2377
2024
Q2 		$44.7K Buy
10,597
+127
+1% +$514 ﹤0.01% 2381
2024
Q1 		$53.3K Sell
10,470
-247
-2% -$1.39K ﹤0.01% 2371
2023
Q4 		$99.8K Buy
+10,717
New +$73.8K ﹤0.01% 2344
2022
Q3 		– Sell
-17,097
Closed -$171K – 2707
2022
Q2 		$171K Sell
17,097
-10,900
-39% -$103K ﹤0.01% 2382
2022
Q1 		$240K Buy
27,997
+5,404
+24% +$66.5K ﹤0.01% 2366
2021
Q4 		$392K Buy
22,593
+10,783
+91% +$205K ﹤0.01% 2289
2021
Q3 		$212K Buy
+11,810
New +$235K ﹤0.01% 2505

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Victory Capital Management's AVXL Position: Q2 2026 in Review

Victory Capital Management increased its Anavex Life Sciences (AVXL) stake by 1% in Q2 2026, buying an estimated $308 and bringing the position to 10,379 shares worth $26.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2434.

Victory Capital Management first reported a position in AVXL in Q3 2021 and has held it in 11 quarters since. The position peaked at $392K in Q4 2021. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • Victory Capital Management held 10,379 shares of Anavex Life Sciences worth $26.9K as of Q2 2026.
  • Victory Capital Management bought 104 Anavex Life Sciences shares in Q2 2026, an estimated $308.
  • Anavex Life Sciences made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #2434 holding.
  • Victory Capital Management first reported a position in Anavex Life Sciences in Q3 2021 and has held it in 11 quarters since.
  • Victory Capital Management's Anavex Life Sciences position peaked at $392K in Q4 2021.
  • 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.